NVCR NovoCure Ltd

Price (delayed)

$75.46

Market cap

$7.89B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

$8.28B

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights
NVCR's EPS is up by 38% since the previous quarter and by 38% year-on-year
The net income has grown by 37% from the previous quarter and by 37% YoY
The company's quick ratio rose by 12% QoQ but it fell by 8% YoY

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
104.59M
Market cap
$7.89B
Enterprise value
$8.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
18.08
Price to sales (P/S)
14.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.35
Earnings
Revenue
$539.37M
EBIT
-$21.74M
EBITDA
-$11.55M
Free cash flow
$49.68M
Per share
EPS
-$0.35
Free cash flow per share
$0.48
Book value per share
$4.17
Revenue per share
$5.18
TBVPS
$11.04
Balance sheet
Total assets
$1.15B
Total liabilities
$714.33M
Debt
$577.84M
Equity
$435.88M
Working capital
$952.78M
Liquidity
Debt to equity
1.33
Current ratio
8.46
Quick ratio
8.23
Net debt/EBITDA
-33.45
Margins
EBITDA margin
-2.1%
Gross margin
79.1%
Net margin
-6.8%
Operating margin
-4%
Efficiency
Return on assets
-3.2%
Return on equity
-8.8%
Return on invested capital
-1.8%
Return on capital employed
-2.1%
Return on sales
-4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
2.18%
1 week
8.58%
1 month
-3.9%
1 year
-59.55%
YTD
0.51%
QTD
8.58%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$539.37M
Gross profit
$426.45M
Operating income
-$21.74M
Net income
-$36.54M
Gross margin
79.1%
Net margin
-6.8%
NovoCure's operating margin has surged by 52% QoQ and by 52% YoY
NovoCure's operating income has surged by 51% QoQ and by 51% YoY
NovoCure's net margin has increased by 38% from the previous quarter and by 38% YoY
The net income has grown by 37% from the previous quarter and by 37% YoY

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
N/A
P/B
18.08
P/S
14.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.35
NVCR's EPS is up by 38% since the previous quarter and by 38% year-on-year
The price to book (P/B) is 44% lower than the last 4 quarters average of 31.4 and 42% lower than the 5-year quarterly average of 30.6
The equity has increased by 17% year-on-year and by 6% since the previous quarter
NVCR's price to sales (P/S) is 39% lower than its last 4 quarters average of 23.5 and 28% lower than its 5-year quarterly average of 19.7

Efficiency

How efficient is NovoCure business performance
NovoCure's ROIC has soared by 71% YoY and by 53% from the previous quarter
The company's return on assets has surged by 58% YoY and by 40% QoQ
NVCR's return on sales has surged by 52% since the previous quarter and by 52% year-on-year
NovoCure's return on equity has increased by 46% YoY and by 40% QoQ

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 61% more than its total liabilities
The company's current ratio rose by 12% QoQ but it fell by 8% YoY
The company's quick ratio rose by 12% QoQ but it fell by 8% YoY
NovoCure's debt is 33% more than its equity
The equity has increased by 17% year-on-year and by 6% since the previous quarter
NVCR's debt to equity is down by 14% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.